[Metabolic consequences of long-term antihypertensive treatment with co-dergocrine mesylate/nifedipine in high age groups].
Possible metabolic changes during chronic treatment is of specific importance for the development of antihypertensive drugs. The impact of a combination treatment with co-dergocrine mesilate/nifedipine (Pontuc; CAS 8067-24-1 resp. CAS 21829-25-4) on the lipid metabolism as well as hematological and biochemical values was evaluated in a group of hypertensive patients. HDL-cholesterol remained unchanged, whereas total cholesterol and LDL-cholesterol slightly decreased, apoprotein AI increased and apoprotein B decreased. In conclusion the results of this study indicate that co-dergocrine mesilate/nifedipine has no negative impact on the lipid metabolism in patients with essential hypertension.
Ritter
M M
MM
Medizinische Klinik II, Klinikum Grosshadern, München.
Richter
W O
WO
Schwandt
P
P
D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004338:Drug Combinations; D004877:Ergoloid Mesylates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000009:adverse effects*
D000959:Antihypertensive Agents; D004338:Drug Combinations; D008074:Lipoproteins; D004877:Ergoloid Mesylates; D002784:Cholesterol; D009543:Nifedipine
Metabolische Konsequenzen einer antihypertensiven Langzeitbehandlung mit Co-dergocrinmesilat/Nifedipin im hohen Lebensalter.